Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Non-Muscle Invasive Bladder Neoplasms 2Head and Neck Neoplasms 2Voice Disorders 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomatitis 1Squamous Cell Carcinoma of Head and Neck 1Pleural Diseases 1Papilloma 1Ototoxicity 1Mesothelioma 1Laryngeal Neoplasms 1Hearing Loss 1Goiter 1Esophageal Neoplasms 1Deglutition Disorders 1Cystitis, Interstitial 1Arthralgia 1

Interventions

Cisplatin 161Fluorouracil 135Paclitaxel 127Radiotherapy 125Oxaliplatin 88Carboplatin 72Docetaxel 71Irinotecan 60pembrolizumab 57Leucovorin 57Capecitabine 57Radiation 48Esophagectomy 44Surgical Procedures, Operative 42Drug Therapy 38Neoadjuvant Therapy 28Cetuximab 25Nivolumab 24Bevacizumab 21camrelizumab 20Trastuzumab 20S 1 (combination) 19Chemoradiotherapy 19Magnetic Resonance Spectroscopy 18Epirubicin 16Albumin-Bound Paclitaxel 16Blood Specimen Collection 15tislelizumab 14Taxes 14Radiotherapy, Intensity-Modulated 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Neoplasms × Hyaluronic Acid × Clear all
NCT06077981 2025-05-01

Comparison of 0.4% Hyaluronic Acid Solution Versus Hydroxyethylamide Solution in Submucosal Endoscopic Resections

Instituto do Cancer do Estado de São Paulo

Phase NA Recruiting
30 enrolled
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡